Compare NNY & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNY | QNCX |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.6M | 167.0M |
| IPO Year | N/A | 2019 |
| Metric | NNY | QNCX |
|---|---|---|
| Price | $8.20 | $0.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 15.2M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.77 | $0.08 |
| 52 Week High | $8.94 | $4.55 |
| Indicator | NNY | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 31.13 |
| Support Level | $8.00 | $0.08 |
| Resistance Level | $8.54 | $0.98 |
| Average True Range (ATR) | 0.13 | 0.01 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 9.09 | 59.84 |
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.